Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-722 and Upadacitinib PK Interaction and Safety in Healthy Adults
NCT07425899Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1 trial of ABBV-722 (6 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum observed plasma concentration at steady state of ABBV-722, Time to maximum observed plasma concentration of ABBV-722 and 7 more. Started Feb 2026; status: completed.
02
Drugs
ABBV-722
Beyond the preview
Go deeper on NCT07425899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425899.